The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Xerostomia Therapeutics Market Over The 2026–2030 Period?
The xerostomia therapeutics market has experienced consistent expansion over recent years. It is projected to increase from $2.24 billion in 2025 to $2.35 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.0%. This market’s historical growth can be attributed to factors such as an aging population, the widespread use of xerogenic drugs, the rising prevalence of chronic diseases, increased dental awareness, and hospital-based symptom management.
The xerostomia therapeutics market size is projected to experience consistent growth over the coming years. It is anticipated to expand to $2.79 billion by 2030, showing a compound annual growth rate (CAGR) of 4.3%. This expansion during the forecast period is attributable to factors such as increased availability of over-the-counter (OTC) products, a rise in side effects from cancer therapies, growing self-medication tendencies, broader pharmacy network expansion, and an elevated emphasis on quality of life treatments. Significant trends during this period encompass a rising incidence of dry mouth caused by medication, an increasing demand for over-the-counter therapies, greater adoption of artificial saliva products, the proliferation of retail and mail-order pharmacies, and a heightened focus on managing oral symptoms.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp
What Underlying Factors Are Accelerating The Growth Of The Xerostomia Therapeutics Market?
The increasing occurrence of chronic illnesses is anticipated to fuel the expansion of the xerostomia therapeutics market moving forward. These long-term medical conditions persist for extended periods, often developing gradually and necessitating continuous care. A key factor behind the growing prevalence of chronic diseases is inactive lifestyles, which contribute to issues such as obesity, cardiovascular problems, and diabetes. Xerostomia treatments assist individuals with chronic conditions by easing dry mouth symptoms, thereby enhancing oral health, nutritional intake, and adherence to medications, all vital for managing persistent health issues. For example, as reported by the National Health Service in June 2024, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) had a diagnosis of non-diabetic hyperglycemia or pre-diabetes in 2023. This condition, characterized by elevated blood sugar levels not yet meeting diabetes criteria, represented an 18% increase from 3,065,825 cases recorded in 2022. Consequently, the rising incidence of chronic diseases is propelling the growth of the xerostomia therapeutics market.
How Is The Xerostomia Therapeutics Market Segmented Across Key Categories?
The xerostomia therapeutics market covered in this report is segmented –
1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets
3) By End-User: Adult, Pediatric
Subsegments:
1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes
2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges
Which Upcoming Trends Are Expected To Influence The Xerostomia Therapeutics Market?
Companies prominent in the xerostomia therapeutics market are prioritizing patient-centric, non-invasive therapies, particularly oral sprays, which offer accurate topical lubrication and a protective coating throughout the mouth to alleviate dry-mouth indications and bolster oral well-being. These xerostomia-specific oral sprays are preparations dispensed as a fine mist directly onto the oral mucous membranes (such as the tongue, palate, and inner cheeks), creating either a hydrating layer or a lipid-based film. This action helps to diminish moisture loss, improve lubrication during activities like chewing, swallowing, and speaking, and provide sustained relief for individuals susceptible to dry mouth. An example is K Pharmaceuticals, a US-based pharmaceutical company, which introduced Aquoral in July 2023. This clinically validated oral spray for xerostomia management employs patented Oxidized Glycerol Triesters (OGT) lipid technology to establish a durable protective barrier within the oral cavity, delivering up to six hours of relief with just two quick sprays, thereby decreasing the necessity for repeated applications compared to water-based alternatives.
Who Are The Dominant Players Shaping The Xerostomia Therapeutics Market Landscape?
Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd.
Read the full xerostomia therapeutics market report here:
https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report
Which Region Is Projected To Dominate The Xerostomia Therapeutics Market During The Forecast Period?
North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Xerostomia Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15700&type=smp
Browse Through More Reports Similar to the Global Xerostomia Therapeutics Market 2026, By The Business Research Company
Xerostomia Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report
Leukemia Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report
Mantle Cell Lymphoma Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model